436 related articles for article (PubMed ID: 30504327)
1. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
Fajgenbaum DC
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):318-325. PubMed ID: 30504327
[TBL] [Abstract][Full Text] [Related]
2. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
Fajgenbaum DC
Blood; 2018 Nov; 132(22):2323-2330. PubMed ID: 30487129
[TBL] [Abstract][Full Text] [Related]
3. Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease.
Nabel CS; Sameroff S; Shilling D; Alapat D; Ruth JR; Kawano M; Sato Y; Stone K; Spetalen S; Valdivieso F; Feldman MD; Chadburn A; Fosså A; van Rhee F; Lipkin WI; Fajgenbaum DC
PLoS One; 2019; 14(6):e0218660. PubMed ID: 31242229
[TBL] [Abstract][Full Text] [Related]
4. Overview of Castleman disease.
Dispenzieri A; Fajgenbaum DC
Blood; 2020 Apr; 135(16):1353-1364. PubMed ID: 32106302
[TBL] [Abstract][Full Text] [Related]
5. Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease.
Pierson SK; Stonestrom AJ; Shilling D; Ruth J; Nabel CS; Singh A; Ren Y; Stone K; Li H; van Rhee F; Fajgenbaum DC
Am J Hematol; 2018 Jul; 93(7):902-912. PubMed ID: 29675946
[TBL] [Abstract][Full Text] [Related]
6. TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease.
Srkalovic G; Marijanovic I; Srkalovic MB; Fajgenbaum DC
Bosn J Basic Med Sci; 2017 May; 17(2):81-84. PubMed ID: 28135567
[TBL] [Abstract][Full Text] [Related]
7. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease.
Fajgenbaum DC; Langan RA; Japp AS; Partridge HL; Pierson SK; Singh A; Arenas DJ; Ruth JR; Nabel CS; Stone K; Okumura M; Schwarer A; Jose FF; Hamerschlak N; Wertheim GB; Jordan MB; Cohen AD; Krymskaya V; Rubenstein A; Betts MR; Kambayashi T; van Rhee F; Uldrick TS
J Clin Invest; 2019 Aug; 129(10):4451-4463. PubMed ID: 31408438
[TBL] [Abstract][Full Text] [Related]
8. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.
Fajgenbaum DC; Uldrick TS; Bagg A; Frank D; Wu D; Srkalovic G; Simpson D; Liu AY; Menke D; Chandrakasan S; Lechowicz MJ; Wong RS; Pierson S; Paessler M; Rossi JF; Ide M; Ruth J; Croglio M; Suarez A; Krymskaya V; Chadburn A; Colleoni G; Nasta S; Jayanthan R; Nabel CS; Casper C; Dispenzieri A; Fosså A; Kelleher D; Kurzrock R; Voorhees P; Dogan A; Yoshizaki K; van Rhee F; Oksenhendler E; Jaffe ES; Elenitoba-Johnson KS; Lim MS
Blood; 2017 Mar; 129(12):1646-1657. PubMed ID: 28087540
[TBL] [Abstract][Full Text] [Related]
9. [Recent advances in diagnosis and treatment of idiopathic multicentric Castleman disease].
Okamoto S
Rinsho Ketsueki; 2019; 60(9):1205-1211. PubMed ID: 31597845
[TBL] [Abstract][Full Text] [Related]
10. Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series.
Lust H; Gong S; Remiker A; Rossoff J
Pediatr Blood Cancer; 2021 Oct; 68(10):e29261. PubMed ID: 34302703
[TBL] [Abstract][Full Text] [Related]
11. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?
Fujimoto S; Sakai T; Kawabata H; Kurose N; Yamada S; Takai K; Aoki S; Kuroda J; Ide M; Setoguchi K; Tsukamoto N; Iwao-Kawanami H; Kawanami T; Mizuta S; Fukushima T; Masaki Y
Am J Hematol; 2019 Sep; 94(9):975-983. PubMed ID: 31222819
[TBL] [Abstract][Full Text] [Related]
12. TAFRO Syndrome: A Syndrome or a Subtype of Multicentric Castleman Disease?
Takai K
Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540266
[TBL] [Abstract][Full Text] [Related]
13. Hepatic Campylobacter jejuni infection in patients with Castleman-Kojima disease (idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome).
Kageyama C; Igawa T; Gion Y; Iwaki N; Tabata T; Tanaka T; Kondo E; Sakai H; Tsuneyama K; Nomoto K; Noguchi H; Yoshino T; Yokota K; Sato Y
Pathol Int; 2019 Oct; 69(10):572-579. PubMed ID: 31631463
[TBL] [Abstract][Full Text] [Related]
14. Multicentric Castlemans disease. Symptoms, diagnostics and therapy.
Adam Z; Řehák Z; Adamová Z; Koukalová R; Pour L; Krejčí M; Boichuk I; Sandecká V; Krejčí M; Štork M; Ševčíková S; Král Z
Vnitr Lek; 2022; 68(1):41-53. PubMed ID: 35459346
[TBL] [Abstract][Full Text] [Related]
15. Castleman disease.
Carbone A; Borok M; Damania B; Gloghini A; Polizzotto MN; Jayanthan RK; Fajgenbaum DC; Bower M
Nat Rev Dis Primers; 2021 Nov; 7(1):84. PubMed ID: 34824298
[TBL] [Abstract][Full Text] [Related]
16. Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease.
Pierson SK; Shenoy S; Oromendia AB; Gorzewski AM; Langan Pai RA; Nabel CS; Ruth JR; Parente SAT; Arenas DJ; Guilfoyle M; Reddy M; Weinblatt M; Shadick N; Bower M; Pria AD; Masaki Y; Katz L; Mezey J; Beineke P; Lee D; Tendler C; Kambayashi T; Fosså A; van Rhee F; Fajgenbaum DC
Blood Adv; 2021 Sep; 5(17):3445-3456. PubMed ID: 34438448
[TBL] [Abstract][Full Text] [Related]
17. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease.
Nishimura Y; Fajgenbaum DC; Pierson SK; Iwaki N; Nishikori A; Kawano M; Nakamura N; Izutsu K; Takeuchi K; Nishimura MF; Maeda Y; Otsuka F; Yoshizaki K; Oksenhendler E; van Rhee F; Sato Y
Am J Hematol; 2021 Oct; 96(10):1241-1252. PubMed ID: 34265103
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in Castleman Disease.
Hoffmann C; Hentrich M; Tiemann M; Rosenwald A; Weber F; Willenbacher W; Hübel K
Oncol Res Treat; 2022; 45(11):693-704. PubMed ID: 36219975
[TBL] [Abstract][Full Text] [Related]
19. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
van Rhee F; Voorhees P; Dispenzieri A; Fosså A; Srkalovic G; Ide M; Munshi N; Schey S; Streetly M; Pierson SK; Partridge HL; Mukherjee S; Shilling D; Stone K; Greenway A; Ruth J; Lechowicz MJ; Chandrakasan S; Jayanthan R; Jaffe ES; Leitch H; Pemmaraju N; Chadburn A; Lim MS; Elenitoba-Johnson KS; Krymskaya V; Goodman A; Hoffmann C; Zinzani PL; Ferrero S; Terriou L; Sato Y; Simpson D; Wong R; Rossi JF; Nasta S; Yoshizaki K; Kurzrock R; Uldrick TS; Casper C; Oksenhendler E; Fajgenbaum DC
Blood; 2018 Nov; 132(20):2115-2124. PubMed ID: 30181172
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease.
Iwaki N; Fajgenbaum DC; Nabel CS; Gion Y; Kondo E; Kawano M; Masunari T; Yoshida I; Moro H; Nikkuni K; Takai K; Matsue K; Kurosawa M; Hagihara M; Saito A; Okamoto M; Yokota K; Hiraiwa S; Nakamura N; Nakao S; Yoshino T; Sato Y
Am J Hematol; 2016 Feb; 91(2):220-6. PubMed ID: 26805758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
